NCT00826618View on ClinicalTrials.gov

Pilot Study of Ranibizumab (Lucentis) for Uveitic Cystoid Macular Edema

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

September 30, 2012

Study Completion Date

September 30, 2013

Conditions
Uveitic Cystoid Macular Edema
Interventions
DRUG

ranibizumab

This is an open-label, Phase I study of intravitreally administered 0.5mg ranibizumab in subjects with uveitic CME.

Trial Locations (2)

33136

Bascom Palmer Eye Insitute, Miami

33418

Bascom Palmer of the Palm Beaches, Palm Beach Gardens

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

University of Miami

OTHER